Prostate-Specific Antigen (PSA): Total PSA, Free/Total Ratio, PSA Kinetics, and Age-Adjusted Thresholds

Prostate-Specific Antigen (PSA), also designated human kallikrein-3 (hK3), is a 33 kDa single-chain glycoprotein synthesized almost exclusively by the secretory columnar epithelial cells lining the acini and ducts of the human prostate gland. PSA is a chymotrypsin-like serine protease whose gene is located on chromosome 19q13.3 and is strictly regulated by androgen receptor signaling.

The physiological role of PSA occurs outside the vascular system:

• High concentrations (0.5–2.0 mg/mL, up to 10⁶-fold higher than in blood) are secreted into seminal fluid.
• PSA cleaves high-molecular-weight gel-forming proteins (semenogelin I and II and fibronectin) in the seminal coagulum, liquefying the seminal clot within 15 to 30 minutes after ejaculation to enable sperm motility and fertilization.

In a healthy prostate, anatomical barriers (epithelial basement membrane, prostatic stroma, and capillary endothelium) prevent PSA from leaking into the systemic circulation. Only minute trace amounts enter the bloodstream. Disruption of these tissue barriers by prostate adenocarcinoma, benign prostatic hyperplasia (BPH), acute prostatitis, or mechanical trauma allows glandular PSA to diffuse into the capillary bed, elevating serum levels.

In the circulation, PSA exists in two primary molecular forms:

1. Complexed PSA (cPSA): 70–90% of circulating PSA is bound irreversibly to endogenous protease inhibitors, predominantly $\alpha_1$-antichymotrypsin (ACT) and to a lesser extent α₂-macroglobulin.
2. Free PSA (fPSA): 10–30% circulates as uncomplexed, enzymatically inactive fragments (including pro-PSA, BPH-associated PSA, and intact free PSA).

Pre-analytic mechanical and physiological factors can substantially distort total PSA measurements:

Prostate volume naturally enlarges with age due to benign hyperplasia, leading to higher physiological baseline PSA:

1. Shared Decision-Making Screening: Well-informed men aged 50 to 69 years with ≥ 10-year life expectancy; early screening from age 40–45 years in high-risk populations (African ancestry, first-degree relative with early prostate cancer, or BRCA2/BRCA1 carriers).
2. Evaluation of Abnormal Digital Rectal Examination: Palpable nodule, focal induration, asymmetry, or loss of lateral sulcus.
3. Assessment of Lower Urinary Tract Symptoms (LUTS): Hesitancy, weak stream, nocturia, post-void dribbling (establishing BPH baseline prior to medical/surgical therapy).
4. Post-Treatment Oncologic Surveillance:

• Monitoring for biochemical recurrence following radical prostatectomy (cutoff ≥ 0.2 ng/mL).
• Monitoring following external beam radiotherapy or brachytherapy (**Phoenix criteria: nadir } + 2.0\text{ ng/mL}$).

1. Response Evaluation in Advanced / Metastatic Disease: Assessing efficacy of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors.

Step 1: Check History for Confounders and 5-Alpha Reductase Inhibitors
   ├─ Patient taking Finasteride / Dutasteride? ──> MULTIPLY VALUE BY 2!
   ├─ Acute UTI, prostatitis, catheterization, cycling in last 48h? ──> Postpone test 4-6 weeks
   └─ Repeat borderline PSA in 4-6 weeks to rule out transient physiological spike

Step 2: Evaluate Absolute Total PSA Value
   ├─ PSA < 2.5 ng/mL ──────────────────────────> Normal; resume screening every 2-4 years
   ├─ PSA in Diagnostic Gray Zone (4.0-10.0) ───> Proceed to Step 3 (Secondary Risk Stratification)
   └─ PSA > 10.0 ng/mL ─────────────────────────> High risk; urgent urology referral for mpMRI & Biopsy

Step 3: Secondary Biomarkers in the Gray Zone (4.0 - 10.0 ng/mL)
   ├─ Calculate Free/Total PSA Ratio (%fPSA):
   │     ├─ %fPSA < 10% ───────────────────────> High cancer risk (56%) ──> Proceed to mpMRI and Biopsy
   │     └─ %fPSA > 25% ───────────────────────> Low cancer risk (8%) ───> BPH likely; monitor closely
   └─ Calculate PSA Density (PSAD = Total PSA / Prostate Volume in mL):
         ├─ PSAD >= 0.15 ng/mL/mL ─────────────> Strongly predicts clinically significant cancer
         └─ PSAD < 0.10 ng/mL/mL ──────────────> Favors benign enlargement

Step 4: Image-Guided Biopsy Pathway (EAU / AUA Guidelines)
   ├─ Multiparametric MRI (mpMRI): PI-RADS 4 or 5 ──> Targeted MRI-Ultrasound fusion biopsy
   └─ PI-RADS 1 or 2 with low biomarker risk ─────> Avoid biopsy; longitudinal PSA surveillance

• Pathology: Hyperplasia of the transition zone surrounding the urethra.
• Biochemical Characteristics: Total PSA elevated (4–12 ng/mL), but %fPSA is preserved ($> 20\text{–}25\%$) and PSA density is low ($< 0.10\text{ ng/mL/mL}$).
• PSA rises slowly (< 0.4 ng/mL/year).

• Pathology: Neoplastic proliferation of malignant acini in the peripheral zone (70%).
• Biochemical Characteristics: Rapidly rising PSA, suppressed %fPSA ($< 10\text{–}15\%$), elevated PSA density (≥ 0.15).
• High-grade cancers (Gleason 8–10) with neuroendocrine differentiation may occasionally shed less PSA due to loss of differentiation.

• Marked, acute spike in total PSA (often reaching 30–100 ng/mL) accompanied by high fever, severe dysuria, perineal pain, and pyuria.
• PSA normalizes slowly over 6 to 8 weeks following targeted antibiotic clearance.

1. 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride):

• Block 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT) in prostate stroma and epithelium.
• Suppresses serum PSA by approximately 50% after 6 months of continuous therapy.
• Clinical Rule: Multiply measured PSA by 2. If a patient on finasteride experiences any confirmed increase in PSA above their nadir, immediate evaluation for high-grade cancer is mandatory!

1. Anti-Androgens and GnRH Agonists/Antagonists:

• Androgen deprivation therapy (leuprolide, degarelix, enzalutamide) causes profound chemical castration, dropping PSA to undetectable levels (< 0.02–0.1 ng/mL).

1. Herbal Supplements:

• Saw palmetto (Serenoa repens) and over-the-counter "prostate health" supplements may contain phytoestrogens that mildly alter PSA expression without clear standardization.

• PSA is Organ-Specific, NOT Cancer-Specific: The single greatest limitation of PSA. Elevated PSA reflects prostate architecture disruption, which is far more commonly caused by benign hyperplasia or subclinical prostatitis than cancer. Widespread unstratified screening leads to overdiagnosis and overtreatment of indolent, non-lethal tumors.
• Normal PSA Does Not 100% Exclude Cancer: In the landmark Prostate Cancer Prevention Trial (PCPT), approximately 15% of men with a "normal" PSA (< 4.0 ng/mL) had prostate cancer on biopsy, with 15% of those being high-grade. An abnormal DRE mandates biopsy regardless of PSA!
• Overdiagnosis of Low-Risk Disease: Identifying Gleason 3+3=6 (Grade Group 1) cancer that would never cause symptoms or mortality during the patient's lifetime; modern practice emphasizes active surveillance rather than immediate radical treatment.

> [!CAUTION] > Urgent Clinical Thresholds: > 1. Confirmed Post-Prostatectomy PSA $\ge 0.20\text{ ng/mL}$: Defines Biochemical Recurrence (BCR); represents persistent or metastatic prostate cancer requiring PSMA PET-CT restaging and salvage radiation/ADT. > 2. Post-Radiation PSA Nadir $+ 2.0\text{ ng/mL}$ (Phoenix Definition): Confirms radiation failure / recurrence. > 3. PSA $> 20.0\text{ ng/mL}$ at Initial Presentation: High risk of extensive extracapsular extension, seminal vesicle invasion, and skeletal metastases; requires staging bone scan and CT/MRI abdomen/pelvis.

• PSA Velocity (PSAV): A rate of rise > 0.75 ng/mL/year (when total PSA is 4–10) or > 0.35 ng/mL/year (when total PSA is < 4) raises strong suspicion of malignancy even if the absolute value is within the normal range.
• PSA Density (PSAD):

$PSAD = frac{Serum Total PSA (ng/mL)}{Prostate Volume (mL) on Ultrasound/MRI}$

• PSAD ≥ 0.15 ng/mL/mL indicates high risk of clinically significant prostate cancer.
• Why Free PSA is Decreased in Cancer: Cancer cells rapidly release unprocessed, enzymatically inactive pro-PSA that binds tightly to circulating α₁-antichymotrypsin, leaving a smaller fraction circulating as free, uncomplexed PSA.

• Routine Urinalysis: Excludes urinary tract infection, microscopic hematuria, or active pyuria that could artificially elevate PSA.
• Renal Function Tests & Serum Creatinine: Assesses obstructive uropathy and post-renal hydronephrosis in advanced BPH or locally invasive prostate carcinoma.
• Complete Blood Count (CBC): Identifies anemia from chronic disease or bone marrow replacement (myelophthisis) in extensive skeletal metastatic disease.